ArticleFuture science OA2026
Mapping ophthalmic research on glycosylation and glycation: a PRISMA-compliant bibliometric and co‑citation analysis.
Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnzymatic glycosylation and non-enzymatic glycation contribute significantly to the pathogenesis of major ocular diseases, particularly diabetic retinopathy (DR), age-related macular degeneration (AMD), glaucoma, and cataract. However, the knowledge structure and developmental trajectory of glycosylation-related research in ophthalmology remain unclear.
methodsThe literature on the role of enzymatic glycosylation and non-enzymatic glycation modification in ophthalmic diseases from 1997 to 2024 was searched in the core database of Web of Science. Bibliometrics analysis software VOS viewer (version 1.6.20), Citespace (version 6.1.R1), Scimago Graphica (version 6.1.R1), Microsoft Excel 2021.
resultsThis study analyzed 3,221 publications, all results are available on January 4, 2025. Biochemistry & Molecular Biology was the primary subject area. Research has evolved from early exploration of advanced glycation end products and protein kinase C pathways toward inflammation, biomarker discovery, and risk prediction in specific ocular disorders. Increasing attention has also been directed toward glycosylation-based diagnostic markers and potential therapeutic targets.
conclusionThis bibliometric analysis provides an ophthalmology-centered overview of glycosylation and glycation research, identifying DR as the primary research hub while highlighting emerging translational directions in retinal and other ocular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.